Title : Comparative study on quality of life in patients with stable angina taking Trimetazidine or Ranolazine as add-on therapy
Abstract:
Background: Chronic stable angina is the most prevalent symptom of ischemic heart disease and its management is a priority. Trimetazidine and Ranolazine are recommended as add-on drugs to relieve angina in patients who are not controlled on conventional anti-anginal drugs. Angina attacks occurring in patients with stable coronary artery disease interferes with the patient’s daily activity and eventually lead to poor quality of life besides having an impact on mortality statistics. There is lack of study comparing quality of life in patients with stable angina taking Trimetazidine or Ranolazine as add-on drugs.
Aims and Objectives: The purpose of this study was to compare Trimetazidine versus Ranolazine as add-on therapy in patients with stable angina using Seattle Angina Questionnaire-7 (SAQ-7)
Methodology: It was a comparative, 2 group, observational study conducted over a period of 12 months from December 2022 to November 2023 after approval from IEC. Patients with stable angina between the age group of 18 to 70 years were recruited in the study who were prescribed either Trimetazidine or Ranolazine as add-on therapy. A baseline SAQ-7 evaluation was done at the time of recruitment. After 1 month of follow-up period, again a SAQ-7 evaluation was done for all the participants.
Results: Trimetazidine group and Ranolazine group had 70 patients each. During 1 month of follow-up period, 6 patients of both Trimetazidine and Ranolazine group discontinued the treatment. Baseline SAQ7-QoL score was 53.18 in the Trimetazidine group while it was 49.38 in the Ranolazine group (p=0.073). After 1 month of follow-up period, SAQ7-QoL score was 70.31 in the Trimetazidine group while it was 81.88 in the Ranolazine group (p<0.001). This score between the Trimetazidine and Ranolazine group was statistically significant.
Conclusion: Ranolazine was found to be more effective than Trimetazidine in improving the quality of life as add-on therapy in patients with stable angina.
